Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission
Despite the wide availability of antiretroviral drugs, more than 250,000 infants are vertically infected with HIV-1 annually, emphasizing the need for additional interventions to eliminate pediatric HIV-1 infections. Here, we aimed to define humoral immune correlates of risk of mother-to-child transmission (MTCT) of HIV-1, including responses associated with protection in the RV144 vaccine trial. Eighty-three untreated, HIV-1-transmitting mothers and 165 propensity score-matched nontransmitting mothers were selected from the Women and Infants Transmission Study (WITS) of US nonbreastfeeding, HIV-1-infected mothers. In a multivariable logistic regression model, the magnitude of the maternal IgG responses specific for the third variable loop (V3) of the HIV-1 envelope was predictive of a reduced risk of MTCT. Neutralizing Ab responses against easy-to-neutralize (tier 1) HIV-1 strains also predicted a reduced risk of peripartum transmission in secondary analyses. Moreover, recombinant maternal V3-specific IgG mAbs mediated neutralization of autologous HIV-1 isolates. Thus, common V3-specific Ab responses in maternal plasma predicted a reduced risk of MTCT and mediated autologous virus neutralization, suggesting that boosting these maternal Ab responses may further reduce HIV-1 MTCT..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:125 |
|---|---|
| Enthalten in: |
The journal of clinical investigation - 125(2015), 7, Seite 2702-2706 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Permar, Sallie R [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1172/JCI81593 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1962307891 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1962307891 | ||
| 003 | DE-627 | ||
| 005 | 20230513131335.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1172/JCI81593 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1962307891 | ||
| 035 | |a (DE-599)GBVOLC1962307891 | ||
| 035 | |a (PRQ)c1968-13852d881d1d97463322a56c8fccf4533d154f82357ce21f4f735bf2a29306d0 | ||
| 035 | |a (KEY)0002471620150000125000702702maternalhiv1envelopespecificantibodyresponsesandre | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a 44.60 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Permar, Sallie R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Despite the wide availability of antiretroviral drugs, more than 250,000 infants are vertically infected with HIV-1 annually, emphasizing the need for additional interventions to eliminate pediatric HIV-1 infections. Here, we aimed to define humoral immune correlates of risk of mother-to-child transmission (MTCT) of HIV-1, including responses associated with protection in the RV144 vaccine trial. Eighty-three untreated, HIV-1-transmitting mothers and 165 propensity score-matched nontransmitting mothers were selected from the Women and Infants Transmission Study (WITS) of US nonbreastfeeding, HIV-1-infected mothers. In a multivariable logistic regression model, the magnitude of the maternal IgG responses specific for the third variable loop (V3) of the HIV-1 envelope was predictive of a reduced risk of MTCT. Neutralizing Ab responses against easy-to-neutralize (tier 1) HIV-1 strains also predicted a reduced risk of peripartum transmission in secondary analyses. Moreover, recombinant maternal V3-specific IgG mAbs mediated neutralization of autologous HIV-1 isolates. Thus, common V3-specific Ab responses in maternal plasma predicted a reduced risk of MTCT and mediated autologous virus neutralization, suggesting that boosting these maternal Ab responses may further reduce HIV-1 MTCT. | ||
| 650 | 4 | |a Pregnancy Complications, Infectious - immunology | |
| 650 | 4 | |a AIDS Vaccines - pharmacology | |
| 650 | 4 | |a HIV Infections - complications | |
| 650 | 4 | |a HIV Infections - immunology | |
| 650 | 4 | |a Immunoglobulin G - blood | |
| 650 | 4 | |a HIV-1 - immunology | |
| 650 | 4 | |a Peptide Fragments - immunology | |
| 650 | 4 | |a HIV Antibodies - blood | |
| 650 | 4 | |a HIV Infections - transmission | |
| 650 | 4 | |a Antibodies, Neutralizing - blood | |
| 650 | 4 | |a Infectious Disease Transmission, Vertical - prevention & control | |
| 650 | 4 | |a HIV Envelope Protein gp120 - immunology | |
| 650 | 4 | |a Logistics | |
| 650 | 4 | |a Variables | |
| 650 | 4 | |a Plasma | |
| 650 | 4 | |a Antigens | |
| 650 | 4 | |a Human immunodeficiency virus--HIV | |
| 650 | 4 | |a Viruses | |
| 650 | 4 | |a Binding sites | |
| 650 | 4 | |a Studies | |
| 700 | 1 | |a Fong, Youyi |4 oth | |
| 700 | 1 | |a Vandergrift, Nathan |4 oth | |
| 700 | 1 | |a Fouda, Genevieve G |4 oth | |
| 700 | 1 | |a Gilbert, Peter |4 oth | |
| 700 | 1 | |a Parks, Robert |4 oth | |
| 700 | 1 | |a Jaeger, Frederick H |4 oth | |
| 700 | 1 | |a Pollara, Justin |4 oth | |
| 700 | 1 | |a Martelli, Amanda |4 oth | |
| 700 | 1 | |a Liebl, Brooke E |4 oth | |
| 700 | 1 | |a Lloyd, Krissey |4 oth | |
| 700 | 1 | |a Yates, Nicole L |4 oth | |
| 700 | 1 | |a Overman, R Glenn |4 oth | |
| 700 | 1 | |a Shen, Xiaoying |4 oth | |
| 700 | 1 | |a Whitaker, Kaylan |4 oth | |
| 700 | 1 | |a Chen, Haiyan |4 oth | |
| 700 | 1 | |a Pritchett, Jamie |4 oth | |
| 700 | 1 | |a Solomon, Erika |4 oth | |
| 700 | 1 | |a Friberg, Emma |4 oth | |
| 700 | 1 | |a Marshall, Dawn J |4 oth | |
| 700 | 1 | |a Whitesides, John F |4 oth | |
| 700 | 1 | |a Gurley, Thaddeus C |4 oth | |
| 700 | 1 | |a Von Holle, Tarra |4 oth | |
| 700 | 1 | |a Martinez, David R |4 oth | |
| 700 | 1 | |a Cai, Fangping |4 oth | |
| 700 | 1 | |a Kumar, Amit |4 oth | |
| 700 | 1 | |a Xia, Shi-Mao |4 oth | |
| 700 | 1 | |a Lu, Xiaozhi |4 oth | |
| 700 | 1 | |a Louzao, Raul |4 oth | |
| 700 | 1 | |a Wilkes, Samantha |4 oth | |
| 700 | 1 | |a Datta, Saheli |4 oth | |
| 700 | 1 | |a Sarzotti-Kelsoe, Marcella |4 oth | |
| 700 | 1 | |a Liao, Hua-Xin |4 oth | |
| 700 | 1 | |a Ferrari, Guido |4 oth | |
| 700 | 1 | |a Alam, S Munir |4 oth | |
| 700 | 1 | |a Montefiori, David C |4 oth | |
| 700 | 1 | |a Denny, Thomas N |4 oth | |
| 700 | 1 | |a Moody, M Anthony |4 oth | |
| 700 | 1 | |a Tomaras, Georgia D |4 oth | |
| 700 | 1 | |a Gao, Feng |4 oth | |
| 700 | 1 | |a Haynes, Barton F |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of clinical investigation |d Ann Arbor, Mich. : American Society for Clinical Investigation, 1924 |g 125(2015), 7, Seite 2702-2706 |w (DE-627)129078700 |w (DE-600)3067-3 |w (DE-576)01441127X |x 0021-9738 |7 nnns |
| 773 | 1 | 8 | |g volume:125 |g year:2015 |g number:7 |g pages:2702-2706 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1172/JCI81593 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26053661 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1694725802 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_252 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.60 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 125 |j 2015 |e 7 |h 2702-2706 | ||